|
Acute myocardial infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Acute myocardial infarction (AMI) is characterized by chest pain as well as cardiac troponin I (cTnI) and electrocardiography (ECG) changes.
|
31624755 |
2019 |
|
Acute myocardial infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cardiac troponin I (cTnI) is a specific and sensitive biomarker for the early diagnosis of acute myocardial infarction and for the subsequent clinical treatments.
|
29754053 |
2018 |
|
Acute myocardial infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cardiac troponin I (cTnI) was considered as the "gold standard" for acute myocardial infarction (AMI) diagnosis owing to its superior cardiac specificity for cardiac damage and showing little or no changes in patients with a skeletal muscle disease or trauma.
|
30666995 |
2019 |
|
Acute myocardial infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cardiac troponin I (cTnI) and creatine kinase-MB (CK-MB) are important diagnostic biomarkers for acute myocardial infarction (AMI).
|
31553332 |
2019 |
|
Acute myocardial infarction
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A multivariate regression model showed as predictors for AMI the variables ECG data by admittance at the emergency room, previous AMI history, levels of both Mgb at the third hour, and cTnI at the sixth hour after admission.
|
29607545 |
2018 |
|
Acute myocardial infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
A reliable lateral flow immunoassay (LFIA) based on a facile one-step synthesis of single microspheres in combining with immunochromatography technique was developed to establish a new point-of-care test (POCT) for the rapid and early detection of cardiac troponin I (cTnI), a kind of cardiac specific biomarker for acute myocardial infarction (AMI).
|
29735888 |
2018 |
|
Acute myocardial infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A total of 105 patients evaluated for AMI in the emergency departments of 2 teaching hospitals in the Henry Ford Health System (Detroit and West Bloomfield, MI), between February 2014 and May 2015, with a modified HEART score ≤3 (which includes cardiac troponin I <0.04 ng/mL at 0 and 3 hours) were randomized to immediate discharge (n=53) versus management in an observation unit with stress testing (n=52).
|
28954802 |
2017 |
|
Acute myocardial infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Abbreviations: AMI: acute myocardial infarction; cTn: cardiac troponin; cTnI: cardiac troponin I; cTnT: cardiac troponin T; MLKL: mixed lineage kinase domain-like; TUNEL: terminal deoxynucleotidyl transferase nick end labeling.
|
29976112 |
2018 |
|
Acute myocardial infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Advancements in health care monitoring demand a rapid, accurate and reliable early diagnosis of "Heart Attack" (acute myocardial infarction) with an objective to develop a cost-effective, rapid and label-free point of care diagnostic test kit for the detection of cardiac troponin I (cTnI) on paper-based multi-frequency impedimetric transducers.
|
31844990 |
2019 |
|
Acute myocardial infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among those, 40 patients had MI that was detected by catheter coronary angiography and cardiac troponin I elevation and evolution of acute MI detected by electrocardiogram changes.
|
28672916 |
2017 |
|
Acute myocardial infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Because of their cardiac specificity, cardiac troponin I or T are the recommended biomarkers for diagnosing acute myocardial infarction.
|
30797799 |
2019 |
|
Acute myocardial infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Circadian rhythm of cardiac troponin I and its clinical impact on the diagnostic accuracy for acute myocardial infarction.
|
29891238 |
2018 |
|
Acute myocardial infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Direct Comparison of 4 Very Early Rule-Out Strategies for Acute Myocardial Infarction Using High-Sensitivity Cardiac Troponin I.
|
28283497 |
2017 |
|
Acute myocardial infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Due to its myocardial specificity, cTnI is widely used for the diagnosis of AMI diseases.
|
30471567 |
2019 |
|
Acute myocardial infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Early detection of cardiac troponin I (cTnI), B-type natriuretic peptide (BNP), and myoglobin (Myo) is essential for the diagnosis of acute myocardial infarction (AMI) and heart failure (HF).
|
30985109 |
2019 |
|
Acute myocardial infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Evaluating Rapid Rule-out of Acute Myocardial Infarction Using a High-Sensitivity Cardiac Troponin I Assay at Presentation.
|
29419380 |
2018 |
|
Acute myocardial infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further, electrical characterization (Id-Vd) confirms the potentiality of FET-based biosensor to detect cTnI (represents acute myocardial infarction disease) with the concentration ranges from 10 μg/ml down to 1 fg/ml.
|
29458578 |
2018 |
|
Acute myocardial infarction
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, the commendable sensing performance of our proposed ELISA in the determination of the cTnI level in diluted human serum unambiguously illustrates great potential in the early diagnosis of acute myocardial infarction.
|
31124658 |
2019 |
|
Acute myocardial infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Gender-specific diagnostic performance of a new high-sensitivity cardiac troponin I assay for detection of acute myocardial infarction.
|
26772795 |
2017 |
|
Acute myocardial infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Highly sensitive detection of cTnI is of paramount importance regarding the rapid rule-in/rule-out of acute myocardial infarction (AMI).
|
30469415 |
2018 |
|
Acute myocardial infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Human cardiac troponin I (cTnI) has been regarded as a golden biomarker for AMI due to its excellent selectivity.
|
29725733 |
2018 |
|
Acute myocardial infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition to mAbs specific to the central part of cTnI (approximately aar 34-126), antibodies specific to the adjacent epitopes (approximately aar 23-36 and 126-196) could be used in assays because they recognize ≥80% of cTnI in patients' blood samples within the first 36 h after AMI.
|
29632125 |
2018 |
|
Acute myocardial infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, the ATR1 A1166C polymorphism is associated with AMI and the CC genotype associated with increased ACE activity and cTnI levels appear to predispose for AMI risk.
|
21330421 |
2011 |
|
Acute myocardial infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, an enzyme linked DNA aptamer based assay was optimized for human cardiac troponin I (cTnI) detection which is a prominent biomarker for acute myocardial infarction (AMI), on an integrated microfluidic platform.
|
31317135 |
2019 |
|
Acute myocardial infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, in order to rapidly detect AMI disease, the authors fabricated a label-free electrochemical biosensor composed of a multi-functional DNA structure on Au nanospike (AuNS) with a fabricated Au micro-gap electrode which was incorporated with a PCB chip in order to detect cardiac troponin I (cTnI).
|
30554012 |
2019 |